Viral and cellular RNA helicases as antiviral targets

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 845-853

  Kwong, Ann D ^a   Rao, B Govinda ^a   Jeang, Kuan Teh ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ANTIVIRUS AGENT; CELL ENZYME; CILUPREVIR; ENZYME INHIBITOR; HELICASE DDX3; HELICASE NS3; NEW DRUG; PROTEINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REV PROTEIN; RNA HELICASE; SULFATHIAZOLE; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS ENZYME; VIRUS PROTEIN; VIRUS RNA; VX 950;

ANTIVIRAL ACTIVITY; CONSENSUS SEQUENCE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME CONFORMATION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN MOTIF; REVIEW; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HUMANS; RNA HELICASES; RNA, VIRAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 27644446534     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1853     Document Type: Review

References (90)

1. De Clercq, E. Antivirals and antiviral strategies. Nature Rev. Microbiol. 2, 704-720 (2004).
2. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13-25 (2002).
3. Richman, D. D. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res. 29, 31-33 (1996).
4. Lohman, T. M. & Bjornson, K. P. Mechanisms of helicase-catalyzed DNA unwinding. Annu. Rev. Biochem. 65, 169-214 (1996).
5. Soultanas, P. & Wigley, D. B. Unwinding the 'Gordian knot' of helicase action. Trends Biochem. Sci. 26, 47-54 (2001).
6. Singleton, M. R. & Wigley, D. B. Modularity and specialization in superfamily 1 and 2 helicases. J. Bacteriol. 184, 1819-1826 (2002).
7. Levin, M. K. & Patel, S. S. in Molecular Motors (ed. Schliwa, M.) 179-198 (Wiley-VCH Weinheim, 2002).
8. Gorbalenya, A. E. & Koonin, E. V. Helicases: Amino acid sequence comparisons and structure function relationships. Curr. Opin. Struc. Biol. 3, 419-429 (1993).
9. Caruthers, J. & McKay, D. Helicase structure and mechanism. Curr. Opin. Struct. Biol. 12, 123-133 (2002).
10. Kim, J. et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding. Structure 6, 89-100 (1998).
11. Subramanya, H. S., Bird, L. E., Brannigan, J. A. & Wigley, D. B. Crystal structure of a DExx box DNA helicase. Nature 384, 379-383 (1996).
12. Walker, J. E., M., S., Runswick, M. J. & Gay, N. J. Distantly related sequences in the α- and β-subunits of ATP synthetase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1, 945-951 (1982).
13. Kim, D. W., Kim, J., Gwack, Y., Han, J. H. & Choe, J. Mutational analysis of the hepatitis C Virus RNA Helicase. J. Virol. 71, 9400-9409 (1997).
14. Kwong, A. D., Kim, J. L. & Lin, C. Structure and function of hepatitis C virus NS3 helicase. Curr. Top. Microbiol. Immunol. 242, 171-196 (2000).
15. Linder, P. et al. Birth of the D-E-A-D box. Nature 337, 121-122 (1989).
16. Lorsch, J. R. RNA chaperones exist and DEAD box proteins get a life. Cell 109, 797-800 (2002).
17. Tanner, N. K. & Linder, P. DExD/H box RNA helicases: From generic motors to specific dissociation functions. Mol. Cell 8, 251-262 (2001).
18. Luking, A., Stahl, U. & Schmidt, U. The protein family of RNA helicases. Crit. Rev. Biochem. Mol. Biol. 33, 259-296 (1998).
19. Linder, P. & Stutz, F. mRNA export: Travelling with DEAD box proteins. Curr. Biol. 11, R961-R963 (2001).
20. de la Cruz, J., Kressler, D. & Linder, P. Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. Trends Biochem. Sci. 24, 192-198 (1999).
21. Kessler, M. M. et al. Hrp1, a sequence-specific RNA-binding protein that shuttles between the nucleus and the cytoplasm, is required for mRNA 3′-end formation in yeast. Genes Dev. 11, 2545-2556 (1997).
22. Dreyfuss, G., Kim, V. N. & Kataoka, N. Messenger-RNA-binding proteins and the messages they carry. Nature Rev. Mol. Cell Biol. 3, 195-205 (2002).
23. Fairman, M. E. et al. Protein displacement by DExH/D "RNA helicases" without duplex unwinding. Science 304, 730-734 (2004).
24. Rocak, S. & Linder, P. DEAD-box proteins: The driving forces behind RNA metabolism. Nature Rev. Mol. Cell. Biol. 5, 232-241 (2004).
25. Tseng, S. S. et al. Dbp5p, a cytosolic RNA helicase, is required for poly(A)+ RNA export. EMBO J. 17, 2651-2662 (1998).
26. Schmitt, C. et al. Dbp5, a DEAD-box protein required for mRNA export, is recruited to the cytoplasmic fibrils of nuclear pore complex via a conserved interaction with CAN/Nup159p. EMBO J. 18, 4332-4347 (1999).
27. Yedavalli, V. S., Neuveut, C., Chi, Y. H., Kleiman, L. & Jeang, K. T. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119, 381-392 (2004).
28. Daugeron, M. C. & Linder, P. Dbp7p, a putative ATP-dependent RNA helicase from Saccharomyces cerevisiae, is required for 60S ribosomal subunit assembly. RNA 4, 566-581 (1998).
29. Liang, W. Q., Clark, J. A. & Fournier, M. J. The rRNA-processing function of the yeast U14 small nucleolar RNA can be rescued by a conserved RNA helicase-like protein. Mol. Cell Biol. 17, 4124-4132 (1997).
30. Koonin, E. V. & Dolja, V. V. Evolution and taxonomy of positive-strand RNA viruses: Implications of comparative analysis of amino acid sequences. Crit. Rev. Biochem. Mol. Biol. 28, 375-430 (1993).
31. Fang, J. et al. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology 330, 471-480 (2004).
32. Kleymann, G. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Med. 8, 392-398 (2002).
33. Crumpacker, C. S. & Schaffer, P. A. New anti-HSV therapeutics target the helicase-primase complex. Nature Med. 8, 327-328 (2002).
34. Jones, P. S. Strategies for antiviral drug discovery. Antivir. Chem. Chemother. 9, 283-302 (1998).
35. Frick, D. N. Helicases as antiviral drug targets. Drug News Perspect. 16, 355-362 (2003).
36. Kadaré, G. & Haenni, A.-L. Minireview: Virus-encoded RNA helicases. J. Virol. 71, 2583-2590 (1997).
37. Wilson, V. G., West, M., Woytek, K. & Rangasamy, D. Papillomavirus E1 proteins: Form, function, and features. Virus Genes 24, 275-290 (2002).
38. Marintcheva, B. & Weller, S. K. A tale of two HSV-1 helicases: Roles of phage and animal virus helicases in DNA replication and recombination. Prog. Nucleic Acid Res. Mol. Biol. 70, 77-118 (2001).
39. Crute, J. J. et al. Herpes simplex virus 1 helicase-primase: A complex of three herpes-encoded gene products. Proc. Natl Acad. Sci. USA 86, 2186-2189 (1989).
40. Spector, F. C., Liang, L., Giordano, H., Sivaraja, M. & Peerson, M. G. T157602, a 2-amino-thiazole inhibits HSV replication by interacting with the UL5 component of the UL5/8/52 helicase primase complex. Antiviral Res. 37, A43 (1998).
41. Spector, F. C., Liang, L., Giordano, H., Sivaraja, M. & Peterson, M. G. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol. 72, 6979-6987 (1998).
42. Crute, J. J. et al. Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and-pyrimidines. J. Med. Chem. 38, 1820-1825 (1995).
43. Betz, U. A., Fischer, R., Kleymann, G., Hendrix, M. & Rubsamen-Waigmann, H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antmicrob. Agents Chemother. 46, 1766-1772 (2002).
44. Liuzzi, M. et al. Aminothiazolyl-phenyl-based inhibitors of HSV helicase-primase: A novel class of orally active antiherpetic agents. Antiviral Res. 37, A42 (1998).
45. Kim, J. L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355 (1996).
46. Yao, N. et al. Structure of the hepatitis C virus RNA helicase domain. Nature Struct. Biol. 4, 463-467 (1997).
47. Cho, H.-S. et al. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. J. Biol. Chem. 273, 15045-15052 (1998).
48. Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6, 937-943 (1999).
49. Bressanelli, S, Tomei, L., Rey, F. A. & De Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76, 3482-3492 (2002).
50. Ago, H. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold. Des. 7, 1417-1426 (1999).
51. Salonen, A., Ahola, T. & Kaariainen, L. Viral RNA replication in association with cellular membranes. Curr. Top. Microbiol. Immunol. 285, 139-173 (2005).
52. Ma, H. et al. Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 332, 8-15 (2005).
53. Moradpour, D. et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 78, 13278-13284 (2004).
54. Phoon, C. W., Ng, P. Y., Ting, A. E., Yeo, S. L. & Sim, M. M. Biological evaluation of hepatitis C virus helicase inhibitors. Bioorg. Med. Chem. Lett. 11, 1647-1650 (2001).
55. Rice, C. M. in Virology (eds Fields, B. N., Knipe, D. M. & Howley, P. M.) 931-960 (Raven, New York, 1996).
56. Gallinari, P. et al. Multiple enzymatic activities associated with recombinant NS3 Protein of hepatitis C virus. J. Virol. 72, 6758-6769 (1998).
57. Taremi, S. S. et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7, 2143-2149 (1998).
58. Hong, Z. et al. Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J. Virol. 70, 4261-4268 (1996).
59. Tackett, A. J., Chen, Y., Cameron, C. E. & Raney, K. D. Multiple full-length NS3 molecules are required for optimal unwinding of oligonucleotide DNA in vitro. J. Biol. Chem. 280, 10797-10806 (2005).
60. Frick, D. N., Rypma, R. S., Lam, A. M. & Gu, B. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J. Biol. Chem. 279, 1269-1280 (2004).
61. Kuang, W. F. et al. Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A. Biochem. Biophys. Res. Commun. 317, 211-217 (2004).
62. Morgenstern, K. A. et al. Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells. J. Virol. 71, 3767-3775 (1997).
63. Gallinari, P. et al. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry 38, 5620-5632 (1999).
64. Porter, D. J. A kinetic analysis of the oligonucleotide-modulated ATPase activity of the helicase domain of the NS3 protein from hepatitis C virus. The first cycle of interaction of ATP with the enzyme is unique. J. Biol. Chem. 273, 14247-14253 (1998).
65. 2, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid complex. J. Biol. Chem. 273, 7390-7396 (1998).
66. Porter, D. J. et al. Product release is the major contributor to kcat for the hepatitis C virus helicase-catalyzed strand separation of short duplex DNA. J. Biol. Chem. 273, 18906-18914 (1998).
67. Levin, M. K., Gurjar, M. M. & Patel, S. S. ATP binding modulates the nucleic acid affinity of hepatitis C virus helicase. J. Biol. Chem. 278, 23311-23316 (2003).
68. Serebrov, V. & Pyle, A. M. Periodic cycles of RNA unwinding and pausing by hepatitis C virus NS3 helicase. Nature 430, 476-480 (2004).
69. Borowski, P. et al. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim. Pol. 47, 173-180 (2000).
70. Borowski, P., Schalinski, S. & Schmitz, H. Nucleotide triphosphatase/ helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res. 55, 397-412 (2002).
71. Yao, N. & Weber, P. C. Helicase, a target for novel inhibitors of hepatitis C virus. Antiviral Ther. 3, 93-97 (1998).
72. Lin, C. & Kim, J. L. Structure-based mutagenesis study of hepatitis C virus NS3 helicase. J. Virol. 73, 8798-8807 (1999).
73. Frick, D. N., Rypma, R. S., Lam, A. M. & Frenz, C. M. Electrostatic analysis of the hepatitis C virus NS3 helicase reveals both active and allosteric site locations. Nucleic Acids Res. 32, 5519-5528 (2004).
74. Lam, A. M., Keeney, D. & Frick, D. N. Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action. J. Biol. Chem. 278, 44514-44524 (2003).
75. Prabhu, R. et al. Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am. J. Pathol. 165, 1163-1173 (2004).
76. Artsaenko, O., Tessmann, K., Sack, M., Haussinger, D. & Heintges, T. Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies. J. Gen. Virol. 84, 2323-2332 (2003).
77. Hwang, B. et al. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10, 1277-1290 (2004).
78. Nishikawa, F., Funaji, K., Fukuda, K. & Nishikawa, S. In vitro selection of RNA aptamers against the HCV NS3 helicase domain. Oligonucleotides 14, 114-129 (2004).
79. Kwong, A. D. & Risano, C. in Methods in Molecular Medicine (eds Kichington, D. & Schinazi, R.) 97-116 (Humana, Totowa, New Jersey, 1998).
80. Kyono, K., Miyashiro, M. & Taguchi, I. Expression and purification of a hepatitis C virus NS3/4A complex, and characterization of its helicase activity with the scintillation proximity assay system. J Biochem (Tokyo) 135, 245-252 (2004).
81. Boguszewska-Chachulska, A. M. et al. Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett. 567, 253-258 (2004).
82. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
83. Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355 (2004).
84. Reesink, H. et al. Initial results of a Phase 1b multiple dose study of VX-950, a hepatitis C virus protease inhibitor. Digestive Disease Week (Chicago, 2005).
85. Godofsky, E. et al. Phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C. Digestive Disease Week (New Orleans, 2004).
86. Bretner, M. et al. Synthesis and evaluation of ATP-binding site directed potential inhibitors of nucleoside triphosphatases/helicases and polymerases of hepatitis C and other selected Flaviviridae viruses. Antivir. Chem. Chemother. 15, 35-42 (2004).
87. Locatelli, G. A., Spadari, S. & Maga, G. Hepatitis C virus NS3 ATPase/helicase: An ATP switch regulates the cooperativity among the different substrate binding sites. Biochemistry 41, 10332-10342 (2002).
88. Liu, D., Windsor, W. T. & Wyss, D. F. Double-stranded DNA-induced localized unfolding of HCV NS3 helicase subdomain 2. Protein Sci. 12, 2757-2767 (2003).
89. Menard, J. & Patchett, A. A. Angiotensin-converting enzyme inhibitors. Adv. Protein Chem. 56, 13-75 (2001).
90. Zhang, N. et al. Potent inhibition of NTPase/helicase of the West Nile Virus by ring-expanded ("fat") nucleoside analogues. J. Med. Chem. 46, 4776-4789 (2003).